Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - REGENERX BIOPHARMACEUTICALS INC | tm211107d1_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - REGENERX BIOPHARMACEUTICALS INC | tm211107d1_ex31-1.htm |
| 10-K - FORM 10-K - REGENERX BIOPHARMACEUTICALS INC | tm211107d1_10k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Registration Nos. 333-168252, 333-152250 and 333-111386) of RegeneRx Biopharmaceuticals, Inc. (the “Company”) of our report, which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern, dated March 2, 2021, on our audits of the financial statements of RegeneRx Biopharmaceuticals, Inc. as of December 31, 2020 and 2019 and for the years then ended, included in this Annual Report on Form 10-K for the year ended December 31, 2020.
| /s/ CohnReznick LLP | |
| Tysons, Virginia | |
| March 2, 2021 |